Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inform Genomics Inc.

Predicting side effects of specific drug regimens

This article was originally published in Start Up

Executive Summary

While other personalized medicine companies tend to focus on selecting the most effective therapeutic drug, say for cancer, Inform Genomics Inc.’s focus with its lead product is to identify patients who have a genetic predisposition to specific side effects from cancer treatments. The company is looking across vast networks of genes to pinpoint characteristics that spell trouble for a patient. Each genetic profile is unique to the risks associated with a specific drug regimen: a patient’s profile may raise a red flag for severe side effects associated with one regimen, but may show that another regimen may be relatively safe.

You may also be interested in...



Homology Medicines Inc.

Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.

X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.

IO Combos By The Numbers

Over the past five years, pharma companies have cast an increasingly wide research net in search of cancer immunotherapy drug combinations that can help patients who have failed monotherapies.

Topics

Related Companies

UsernamePublicRestriction

Register

SC092360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel